Volume 6, Issue 1, Pages (July 2000)

Slides:



Advertisements
Similar presentations
Volume 4, Issue 12, Pages (December 2015)
Advertisements

Volume 20, Issue 3, Pages (July 2017)
Volume 105, Issue 6, Pages (June 2001)
Volume 126, Issue 3, Pages (March 2004)
Volume 6, Issue 6, Pages (December 2007)
Volume 3, Issue 1, Pages (July 2002)
Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism
Volume 8, Issue 4, Pages (October 2008)
Volume 3, Issue 5, Pages (May 2006)
Volume 16, Issue 10, Pages (September 2016)
Irs1 Serine 307 Promotes Insulin Sensitivity in Mice
Volume 10, Issue 4, Pages (October 2009)
Grzegorz Sumara, Olga Sumara, Jason K. Kim, Gerard Karsenty 
Volume 142, Issue 5, Pages e1 (May 2012)
Volume 12, Issue 6, Pages (December 2010)
Volume 125, Issue 4, Pages (October 2003)
Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism
Volume 18, Issue 2, Pages (August 2013)
Volume 6, Issue 1, Pages (July 2000)
Volume 18, Issue 1, Pages (July 2013)
Volume 6, Issue 3, Pages (September 2007)
Volume 11, Issue 4, Pages (April 2010)
Volume 128, Issue 5, Pages (May 2005)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 134, Issue 3, Pages (March 2008)
Volume 15, Issue 5, Pages (May 2012)
Volume 17, Issue 9, Pages (September 2010)
Volume 18, Issue 13, Pages (March 2017)
Volume 20, Issue 1, Pages (July 2014)
Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo
Volume 7, Issue 4, Pages (May 2014)
Volume 20, Issue 1, Pages (July 2014)
Volume 9, Issue 3, Pages (March 2009)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 88, Issue 4, Pages (February 1997)
Volume 2, Issue 5, Pages (November 1998)
Volume 12, Issue 3, Pages (September 2010)
Heat Shock Transcription Factor 1 Is a Key Determinant of HCC Development by Regulating Hepatic Steatosis and Metabolic Syndrome  Xiongjie Jin, Demetrius.
Volume 23, Issue 6, Pages (June 2016)
Volume 16, Issue 4, Pages (October 2012)
Volume 9, Issue 5, Pages (May 2009)
Volume 6, Issue 4, Pages (October 2007)
Volume 10, Issue 5, Pages (November 2009)
Suppression of β Cell Energy Metabolism and Insulin Release by PGC-1α
Volume 4, Issue 4, Pages (August 2013)
Volume 10, Issue 1, Pages (July 2009)
Volume 14, Issue 1, Pages (July 2011)
Volume 5, Issue 5, Pages (May 2007)
Volume 1, Issue 4, Pages (April 2005)
Volume 24, Issue 8, Pages e7 (August 2018)
Volume 6, Issue 1, Pages (July 2007)
Volume 14, Issue 4, Pages (October 2011)
Volume 96, Issue 3, Pages (February 1999)
Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis  Sarah H. Bates, Rohit N. Kulkarni, Matthew.
Prevention of Steatosis by Hepatic JNK1
Volume 15, Issue 6, Pages (June 2012)
Volume 8, Issue 1, Pages (July 2008)
Leila Khamzina, Philip A Gruppuso, Jack R Wands  Gastroenterology 
Volume 5, Issue 6, Pages (June 2007)
Volume 7, Issue 6, Pages (June 2008)
Mice with AS160/TBC1D4-Thr649Ala Knockin Mutation Are Glucose Intolerant with Reduced Insulin Sensitivity and Altered GLUT4 Trafficking  Shuai Chen, David.
Volume 6, Issue 4, Pages (October 2007)
Volume 4, Issue 5, Pages (November 2006)
Joan Goulley, Ulf Dahl, Nathalie Baeza, Yuji Mishina, Helena Edlund 
Volume 132, Issue 3, Pages (February 2008)
Progressive IGF-1 liver expression, β-cell hyperplasia, and defective insulin secretion with aging in inducible liver-specific insulin receptor knockout.
Evidence against a Physiologic Role for Acute Changes in CNS Insulin Action in the Rapid Regulation of Hepatic Glucose Production  Christopher J. Ramnanan,
Regulation of Gluconeogenesis by Krüppel-like Factor 15
Volume 4, Issue 4, Pages (October 2006)
Presentation transcript:

Volume 6, Issue 1, Pages 87-97 (July 2000) Loss of Insulin Signaling in Hepatocytes Leads to Severe Insulin Resistance and Progressive Hepatic Dysfunction  M.Dodson Michael, Rohit N. Kulkarni, Catherine Postic, Steven F. Previs, Gerald I. Shulman, Mark A. Magnuson, C.Ronald Kahn  Molecular Cell  Volume 6, Issue 1, Pages 87-97 (July 2000) DOI: 10.1016/S1097-2765(05)00015-8

Figure 1 Insulin Receptor Content and Insulin-Stimulated Signaling Are Selectively Abolished in LIRKO Liver (a) Protein extracts were prepared from tissues of 24-day-old wild-type (WT), IR(lox/lox), alb-Cre, and LIRKO mice and subjected to immunoprecipitation (WAT, 1.5 mg; other tissues, 5 mg) with an IR-specific antiserum followed by Western blot analysis with the same antiserum. Signal intensity was quantified using a Storm 840 Phosphorimager (Molecular Dynamics) with ImageQuant 4.0 software. (b) Twenty-four-day-old WT, IR(lox/lox), alb-Cre, and LIRKO mice were stimulated with either saline (−) or 5 U of regular insulin (+) via the inferior vena cava. Liver protein extracts were prepared and subjected to immunoprecipitation of IR (upper panels), IRS-1 (middle panels), and IRS-2 (lower panels) followed by Western blotting with anti-phosphotyrosine antibody (PY), IR antiserum, IRS-1 antiserum, IRS-2 antiserum, or an antiserum to the p85 regulatory subunit of PI 3′-kinase. (c) The experiment was performed as described in (b) with the exception that skeletal muscle was used to prepare the protein lysates. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 2 LIRKO Mice Display Hyperglycemia and Hyperinsulinemia, Glucose Intolerance, and Insulin Resistance (a) Fed blood glucose and serum insulin concentrations were determined from 2-month-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice at 2200–2300 hr (light cycle: 0700 on–1900 off). Each bar represents the mean ± SEM of at least 12 animals of each genotype. (b) Glucose tolerance tests were performed on 2-month-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice that had been fasted for 16 hr. Animals were injected intraperitoneally with 2 g/kg body weight of glucose. Blood glucose was measured immediately before injection and 15, 30, 60, and 120 min after the injection. Results are expressed as mean blood glucose concentration ± SEM from at least eight animals per genotype. (c) Insulin tolerance tests were performed on random-fed, 2-month-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice (performed at 1400 hr). Animals were injected intraperitoneally with 1 U/kg body weight of human regular insulin. Blood glucose was measured immediately before injection and 15, 30, and 60 min after the injection. Results are expressed as mean percent of basal blood glucose concentration ± SEM from at least eight animals per genotype. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 3 Hyperinsulinemia in LIRKO Mice Is Likely Due to Both Increased Insulin Secretion and Decreased Insulin Clearance (a) Pancreatic insulin content was measured in acid-ethanol extracts of pancreas from 6-month-old female WT, IR(lox/lox), alb-Cre, and LIRKO mice by RIA (Linco). Values are expressed as mean ± SEM in pg/mg wet weight of pancreas from four animals per genotype. The lower panel shows a representative Northern blot analysis of total RNA isolated from 60–120 freshly isolated islets from control and LIRKO mice and hybridized with a radiolabeled rat insulin-1 cDNA as probe. (b) Immunostaining for non–β cell hormones was carried out in pancreatic sections from 6-month-old female WT, IR(lox/lox), alb-Cre control mice, and LIRKO mice using a cocktail of antibodies to glucagon, somatostatin, and pancreatic polypeptide. Representative sections from a control and a LIRKO pancreas are shown. (c) To estimate insulin clearance, a ratio of serum levels of C-peptide to insulin was calculated. Serum was obtained from 16-hour-fasted, 11-week-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice. Insulin and C-peptide were determined by RIA (Linco). The decreased C-peptide:insulin ratio in the LIRKO mice reflects decreased insulin clearance. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 4 Hepatic Glucose Production and Expression of Genes Involved in Gluconeogenesis Are Not Suppressed by Insulin in LIRKO Mice (a) Two-month-old male control (WT, IR(lox/lox), and alb-Cre; n = 9) and LIRKO (n = 4) mice were studied by the euglycemic, hyperinsulinemic clamp technique. Mice were infused with [U-13C6]-glucose for 90 min (basal) and then clamped using 2.5 mU human insulin/kg/min (insulin) with glucose maintained at ∼125 mg/dl. Hepatic glucose production during the clamp was determined by subtracting the glucose infusion rate from whole-body glucose appearance. (b) RNA was prepared from liver of 8-week-old, random-fed control (WT, IR(lox/lox), and alb-Cre), and LIRKO mice and was subjected to Northern blotting using probes specific for phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), liver pyruvate kinase (L-PK), and glucokinase (GK). Results are expressed as mean arbitrary phosphorimager units corrected for RNA loading by hybridization to a cyclophilin probe ± SEM from at least four animals per genotype. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 5 Changes in Glucose Metabolism in Older LIRKO Mice May Be Related to Liver Dysfunction (a) Blood glucose concentrations were determined from 2-, 4-, and 6-month-old male wild-type (WT), IR(lox/lox), alb-Cre, and LIRKO mice that had been subjected to a 16 hr fast. Each bar represents the mean ± SEM of at least 12 animals of each genotype. LIRKO mice showed fasting hyperglycemia at 2 months of age, normoglycemia at 4 months of age, and hypoglycemia at 6 months of age. (b) Glucose tolerance tests were repeated as described in Figure 2 on 6-month-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice. Results are expressed as mean blood glucose concentration ± SEM from at least eight animals per genotype. LIRKO mice demonstrated significant normalization of glucose tolerance compared to the GTT performed at 2 months of age (see Figure 2 for comparison). (c) Serum albumin levels were measured from 6-month-old male WT, IR(lox/lox), alb-Cre, and LIRKO mice using an albumin determination kit (Sigma). (d) Liver enzymes were measured in the serum of 6-month-old male IR(lox/lox) control mice (n = 6) and LIRKO mice (n = 6) to assess liver function. Alkaline phosphatase (ALP) and aspartate aminotransferase (AST) were significantly elevated in LIRKO mice. Lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) were not significantly different in LIRKO mice versus controls. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 6 The Liver of Young LIRKO Mice Displays Focal Dysplasia and Impaired Glycogen Storage (a) Hematoxylin and eosin staining of liver sections from random-fed, two-month-old male control (upper panel) and LIRKO (lower panel) mice. The arrow denotes an area of dysplastic cells. Magnification, 10×. (b) Periodic acid-Schiff reagent (PAS) staining of liver sections from random-fed, two-month-old male control (upper panel) and LIRKO (lower panel) mice. Magnification, 4×. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)

Figure 7 The Liver of Aged LIRKO Mice Displays Focal Dysplasia, Hyperplastic Nodules, and Altered Ultrastructural Features (a) Gross appearance of 12-month-old control (upper panel) and LIRKO (lower panel) liver showing hyperplastic nodules and enlarged gallbladder. Magnification, 1.25×. (b) Hematoxylin and eosin staining of liver sections from random-fed, 12-month-old control (upper panel) and LIRKO (lower panel) mice. Note that the nodules appear to compress the adjacent tissue, suggesting that the cells of the nodule are hyperplastic. Magnification, 10×. (c) Electron microscopic analysis of liver sections from random-fed, 6-month-old control (upper panel) and LIRKO (lower panel) mice. Note that the LIRKO hepatocytes exhibit giant mitochondria, few electron-dense glycogen granules, and a moderate increase in lipid content. Magnification, 9690×. Molecular Cell 2000 6, 87-97DOI: (10.1016/S1097-2765(05)00015-8)